Randomized, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

Trial Profile

Randomized, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms Dapa
  • Most Recent Events

    • 30 Aug 2017 Results assessing the effect of dapagliflozin on tissue sodium content, presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 16 Nov 2016 Results assessing the sodium content in the skin and muscles of the lower leg by the Na-MRI at baseline, presented at the 89th Annual Scientific Sessions of the American Heart Association.
    • 29 Sep 2016 Results assessing metabolic parameters, ambulatory blood pressure and sodium content in skin and muscles presented at the 26th Scientific Meeting of the International Society of Hypertension
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top